This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Niethammer, A. G. Articles by Reisfeld, R. A. Search for Related Content PubMed PubMed Citation Articles by Niethammer, A. G. Articles by Reisfeld, R. A.

Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Oral DNA Vaccine against Murine Melanoma¹

Department of Immunology, The Scripps Research Institute, La Jolla, California 92037 [A. G. N., R. X., J. M. R., H. N. L., C. S. D., R. A. R.]; Lexigen Pharmaceuticals Corp., Lexington, Massachusetts 02173 [S. D. G.]; and Charité Children’s Hospital, 13353 Berlin, Germany [H. N. L.]

We demonstrate that a mouse-human chimeric anti-ganglioside GD2-interleukin (IL)-2 fusion protein (ch14.18-IL2) substantially amplifies tumor-protective immunity against murine melanoma induced by an autologous oral DNA vaccine containing the murine ubiquitin gene fused to murine melanoma peptide epitopes gp100_25–35 and TRP-2_181–188. This combination therapy led to the complete rejection of a lethal challenge with B78D14 murine melanoma cells in six of eight mice and a marked suppression of s.c. tumor growth in the two remaining animals. The tumor-protective immunity was mediated by MHC class I antigen- restricted CD8⁺ T cells together with CD4⁺ T cell help, which was required only for tumor cell killing in the effector phase of the immune response. A single oral vaccination with the DNA vaccine, which was carried by attenuated Salmonella typhimurium, was equally as effective as three such vaccinations applied at 2-week intervals. The immunological mechanisms involved in this antitumor effect were suggested by a decisively increased secretion of tumor necrosis factor TNFTnTNa and IFN- from CD4⁺ and CD8⁺ T cells and a markedly up-regulated expression on CD8⁺ T cells of high-affinity IL-2 receptor chain (CD25), costimulatory molecule CD28, and adhesion molecule lymphocyte function-associated antigen-2 (LFA-2/CD2). Additionally, the combination therapy induced increased expression of costimulatory molecules B7.1 and CD48 on murine antigen-presenting cells. Taken together, our results suggest that IL-2 targeted to the tumor microenvironment by a specific antibody-IL-2 fusion protein is a potent enhancer of tumor-protective immunity induced by an oral DNA vaccine that may ultimately enhance the chances of success in its clinical application.

This article has been cited by other articles:

				M. D. Mannie, B. A. Clayson, E. J. Buskirk, J. L. DeVine, J. J. Hernandez, and D. J. Abbott IL-2/Neuroantigen Fusion Proteins as Antigen-Specific Tolerogens in Experimental Autoimmune Encephalomyelitis (EAE): Correlation of T Cell-Mediated Antigen Presentation and Tolerance Induction J. Immunol., March 1, 2007; 178(5): 2835 - 2843. [Abstract] [Full Text] [PDF]

				B. Kim, S. Suvas, P. P. Sarangi, S. Lee, R. A. Reisfeld, and B. T. Rouse Vascular Endothelial Growth Factor Receptor 2-Based DNA Immunization Delays Development of Herpetic Stromal Keratitis by Antiangiogenic Effects J. Immunol., September 15, 2006; 177(6): 4122 - 4131. [Abstract] [Full Text] [PDF]

				E. Bolesta, A. Kowalczyk, A. Wierzbicki, P. Rotkiewicz, B. Bambach, C.-Y. Tsao, I. Horwacik, A. Kolinski, H. Rokita, M. Brecher, et al. DNA Vaccine Expressing the Mimotope of GD2 Ganglioside Induces Protective GD2 Cross-reactive Antibody Responses Cancer Res., April 15, 2005; 65(8): 3410 - 3418. [Abstract] [Full Text] [PDF]

				D. Schrama, R. Xiang, A. O. Eggert, M. H. Andersen, L. O. Pedersen, E. Kampgen, T. N. Schumacher, R. R. Reisfeld, and J. C. Becker Shift from Systemic to Site-Specific Memory by Tumor-Targeted IL-2 J. Immunol., May 15, 2004; 172(10): 5843 - 5850. [Abstract] [Full Text] [PDF]

				U. Pertl, H. Wodrich, J. M. Ruehlmann, S. D. Gillies, H. N. Lode, and R. A. Reisfeld Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma Blood, January 15, 2003; 101(2): 649 - 654. [Abstract] [Full Text] [PDF]

				S. A. Leachman, M. Shylankevich, M. D. Slade, D. Levine, R. K. Sundaram, W. Xiao, M. Bryan, D. Zelterman, R. E. Tiegelaar, and J. L. Brandsma Ubiquitin-Fused and/or Multiple Early Genes from Cottontail Rabbit Papillomavirus as DNA Vaccines J. Virol., June 27, 2002; 76(15): 7616 - 7624. [Abstract] [Full Text] [PDF]